NK-92细胞疗法治疗小儿复发性/难治性尤因肉瘤。
NK-92 cellular therapy for pediatric relapsed/refractory Ewing sarcoma.
作者信息
Yalcin Koray, Ovali Ercument, Ozdamarlar Umut, Celen Suna, Karasu Gulsun, Yesilipek Akif, Hazar Volkan
机构信息
Pediatric Hematology/Oncology and Stem Cell Transplantation Department, Medical Park Goztepe Hospital, Istanbul, Turkey.
Acibadem Labcell Cellular Therapy Center, Istanbul, Turkey.
出版信息
Int Cancer Conf J. 2020 Mar 24;9(3):137-140. doi: 10.1007/s13691-020-00406-6. eCollection 2020 Jul.
Abstract
Relapsed/refractory Ewing sarcoma prognosis is dreadful, especially for recurrences within the first 2 years after initial diagnosis. It is obvious that there is an urgent need for novel treatment strategies for this dismal situation. NK-92 is an activated NK cell line with high cytotoxicity against malignant cells. Here, we present a relapsed/refractory Ewing sarcoma case who had no response to conventional strategies and recieved intratumoral NK-92 cell injections. We observe that intratumoral injection of NK-92 is safe, has no toxicity and shows preliminary evidence of tumor response in relapsed/refractory Ewing Sarcoma.
摘要
复发性/难治性尤因肉瘤的预后很差，尤其是在初次诊断后的头两年内复发的情况。显然，对于这种严峻的情况，迫切需要新的治疗策略。NK-92是一种对恶性细胞具有高细胞毒性的活化自然杀伤细胞系。在此，我们报告一例复发性/难治性尤因肉瘤病例，该病例对传统治疗策略无反应，接受了瘤内注射NK-92细胞治疗。我们观察到，瘤内注射NK-92是安全的，没有毒性，并且在复发性/难治性尤因肉瘤中显示出肿瘤反应的初步证据。
相似文献
1
NK-92 cellular therapy for pediatric relapsed/refractory Ewing sarcoma.
Int Cancer Conf J. 2020 Mar 24;9(3):137-140. doi: 10.1007/s13691-020-00406-6. eCollection 2020 Jul.
2
Ewing's sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing.
Oncology. 1988;45(6):437-43. doi: 10.1159/000226661.
3
Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells.
Oncol Rep. 2013 Jun;29(6):2348-54. doi: 10.3892/or.2013.2350. Epub 2013 Mar 19.
4
Insulin-like growth factor-1 receptor (IGF-1R) inhibition promotes expansion of human NK cells which maintain their potent antitumor activity against Ewing sarcoma cells.
Pediatr Blood Cancer. 2015 Nov;62(11):1979-85. doi: 10.1002/pbc.25619. Epub 2015 Jul 1.
5
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
Mol Immunol. 2008 Sep;45(15):3917-25. doi: 10.1016/j.molimm.2008.06.016. Epub 2008 Jul 26.
6
Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways.
Clin Cancer Res. 2007 Jan 1;13(1):206-14. doi: 10.1158/1078-0432.CCR-06-1457.
7
Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewing's sarcoma patients.
Bone Marrow Transplant. 2015 Jun;50 Suppl 2:S72-6. doi: 10.1038/bmt.2015.100.
8
The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago.
Cell Cycle. 2017 Jun 3;16(11):1046-1052. doi: 10.1080/15384101.2017.1304340. Epub 2017 Mar 15.
9
Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.
Clin Cancer Res. 2012 Jan 15;18(2):432-41. doi: 10.1158/1078-0432.CCR-11-2277. Epub 2011 Nov 16.
10
Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group.
Pediatr Blood Cancer. 2009 Mar;52(3):324-7. doi: 10.1002/pbc.21822.
引用本文的文献
1
The Natural Killer Cell Line NK-92 and Its Genetic Variants: Impact on NK Cell Research and Cancer Immunotherapy.
Cancers (Basel). 2025 Jun 13;17(12):1968. doi: 10.3390/cancers17121968.
2
Natural Killer Cell Activation by Ubiquitin-specific Protease 6 Mediates Tumor Suppression in Ewing Sarcoma.
Cancer Res Commun. 2023 Aug 22;3(8):1615-1627. doi: 10.1158/2767-9764.CRC-22-0505. eCollection 2023 Aug.
3
Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
Int J Mol Sci. 2023 May 5;24(9):8324. doi: 10.3390/ijms24098324.
4
The Role of Natural Killer Cells in Soft Tissue Sarcoma: Prospects for Immunotherapy.
Cancers (Basel). 2021 Jul 31;13(15):3865. doi: 10.3390/cancers13153865.
5
Prospects for NK Cell Therapy of Sarcoma.
Cancers (Basel). 2020 Dec 11;12(12):3719. doi: 10.3390/cancers12123719.
本文引用的文献
1
NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors.
Cytotherapy. 2019 Jun;21(6):603-611. doi: 10.1016/j.jcyt.2019.03.312. Epub 2019 Apr 20.
2
Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy.
Radiol Oncol. 2018 Oct 18;52(4):365-369. doi: 10.2478/raon-2018-0037.
3
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy.
Oncotarget. 2017 Jul 12;8(51):89256-89268. doi: 10.18632/oncotarget.19204. eCollection 2017 Oct 24.
4
NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.
Cancer Immunol Immunother. 2016 Apr;65(4):485-92. doi: 10.1007/s00262-015-1761-x. Epub 2015 Nov 11.
5
Cellular immunotherapy strategies for Ewing sarcoma.
Immunotherapy. 2014;6(5):611-21. doi: 10.2217/imt.14.36.
6
Risk of recurrence and survival after relapse in patients with Ewing sarcoma.
Pediatr Blood Cancer. 2011 Oct;57(4):549-53. doi: 10.1002/pbc.23040. Epub 2011 Mar 25.
7
A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer.
Cancer Immunol Immunother. 2010 Dec;59(12):1781-9. doi: 10.1007/s00262-010-0904-3. Epub 2010 Aug 12.
8
Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer.
Cancer Immunol Immunother. 2009 Apr;58(4):475-92. doi: 10.1007/s00262-008-0598-y. Epub 2008 Oct 17.
9
Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group.
Pediatr Blood Cancer. 2008 Sep;51(3):334-8. doi: 10.1002/pbc.21618.
10
Combined modality immunotherapy and chemotherapy: a new perspective.
Cancer Immunol Immunother. 2008 Oct;57(10):1523-9. doi: 10.1007/s00262-008-0531-4. Epub 2008 May 17.
Zotero 插件